DEC 11, 2019 2:20 PM PST

Drug To Treat Ulcerative Colitis

WRITTEN BY: Nouran Amin

Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmunity symptoms of rheumatoid arthritis can also treat gut permeability defects in patients diagnosed with ulcerative colitis. "Our work increases our understanding of how this drug is useful for treating ulcerative colitis," said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the study that appears in the journal Inflammatory Bowel Diseases. "We now better understand where in the gut the drug is working, and how."

Ulcerative colitis is a chronic inflammatory bowel disease affecting 1 million Americans. The condition targets the large intestine in the digestive system that results in the lining of the colon becoming inflamed and leaky. But, tofacitinib—often marketed as Xeljianz—can repair the cells lining the gut.

"We found tofacitinib fixes the leakiness in the intestinal barrier," McCole said. "Specifically, it fixes intestinal epithelial permeability defects caused by 'interferon-gamma,' an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis."

Learn more about ulcerative colitis:

Intestinal permeability, or leakiness, is a characteristic of ulcerative colitis and results in inflammation. Researchers believe that tofacitinib targets the inflammation-induced permeability in the lining and prevents fluid loss.

"By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation," said Anica Sayoc-Becerra, a graduate student in the Biomedical Sciences Graduate Program, a member of McCole's lab, and the first author of the research paper. "Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function."

Source: University of California

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 27, 2020
Drug Discovery & Development
JAN 27, 2020
Can Aspirin Prevent a Brain Bleed?
Can aspirin prevent a brain bleed? To answer the questions, researchers rummaged through a database system looking to see an association between aspirin us...
JAN 27, 2020
Drug Discovery & Development
JAN 27, 2020
How Fluorescent Probes Can Enhance Drug Delivery
Researchers at Cornell University are working on improving the trial-and-error process that is implicated in finding effective molecules for drug delivery....
JAN 27, 2020
Drug Discovery & Development
JAN 27, 2020
Gene Variant Could Be a Therapeutic Target For Alzheimer Disease
A variation in genetics for an individual at high-risk for Alzheimer development has defied the odds for being dementia-free way beyond anticipated. The in...
JAN 27, 2020
Drug Discovery & Development
JAN 27, 2020
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
JAN 27, 2020
Genetics & Genomics
JAN 27, 2020
Finding a Way to Treat Dangerous Protein Aggregates
The scientists are hopeful that this work will lead to new therapeutics for neurodegenerative disease....
JAN 27, 2020
Drug Discovery & Development
JAN 27, 2020
Treating Malaria: Molecular Understanding of Drug Interactions
Crystallization is a process central to drug development that despite centuries of facilitating a particular method, chemists are still learning how to gra...
Loading Comments...